US Executive Compensation Proxy SEC Filings — July 17, 2026

17-07-2026

Cartesian Growth Corp II (REEUF) is soliciting shareholder approval at an Extraordinary General Meeting on July 27, 2026, to extend the deadline to complete an initial business combination from the current termination date to an extended date. The company raised $236.9M in its IPO and has not yet consummated a deal. Insiders, holding ~65.1% of shares, will vote in favor, but public shareholders may redeem their shares at the trust value if they choose.

• · The company is a blank check company incorporated on October 13, 2021, as a Cayman Islands exempted company.
• · The IPO was consummated on May 10, 2022.
• · The Sponsor loan of $4.6M may be repaid or converted into sponsor loan warrants at $1.00 per warrant, identical to private placement warrants.
• · If the business combination is not completed, the trust account proceeds will be distributed to holders of Class A ordinary shares, and the sponsor loan will not be repaid from trust funds.
• · The Adjournment Proposal will only be presented if there are insufficient votes to approve the Extension Proposal at the meeting.

17-07-2026

Riverview Bancorp Inc. filed its definitive proxy statement (DEF 14A) on July 17, 2026, for the annual meeting of shareholders to be held virtually on August 27, 2026. The meeting will include the election of four directors (two for three-year terms and two for one-year terms), an advisory vote on executive compensation, and approval of the 2026 Stock Purchase Plan. As of the July 1, 2026 record date, there were 20,160,613 shares outstanding, with a 10% voting cap on beneficial owners exceeding that threshold.

• · The annual meeting will be held virtually at www.virtualshareholdermeeting.com/RVSB2026 on August 27, 2026 at 10:00 a.m. local time.
• · Shareholders owning more than 10% of outstanding shares are not entitled to vote on shares held in excess of the 10% limit per the Articles of Incorporation.
• · Proxies with no instructions will be voted FOR all director nominees, FOR advisory approval of executive compensation, and FOR the Stock Purchase Plan.
• · Broker non-votes are expected on all proposals as they are non-discretionary items.
• · The deadline for ESOP and 401(k) Plan participants to return voting instructions is August 22, 2026.

17-07-2026

Tempest Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) on July 17, 2026, for a Special Meeting of Stockholders to be held virtually on July 27, 2026. The sole proposal is to approve a Certificate of Amendment to the company's charter to replace supermajority voting requirements and permit stockholder action by written consent. The record date for the meeting is May 28, 2026, with 14,806,997 shares of common stock outstanding and entitled to vote.

• · The Special Meeting will be held virtually on July 27, 2026, at 12:00 p.m. Eastern Time.
• · The record date for the meeting is May 28, 2026.
• · The proposal is considered 'non-routine' under NYSE rules, meaning brokers cannot vote uninstructed shares on this matter.
• · The proxy materials were mailed to stockholders on or about July 17, 2026.
• · Stockholders can vote by proxy card, telephone, or internet by 11:59 p.m. Eastern Time on July 26, 2026.

17-07-2026

Tivic Health Systems, Inc. (now Valion Bio, Inc.) filed a definitive proxy statement (DEF 14A) on July 17, 2026, seeking stockholder approval for a reverse stock split authorization at a ratio between 1-for-5 and 1-for-50. The primary purpose is to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a deficiency notice on March 19, 2026, with an initial compliance deadline of September 15, 2026. The company's stock closed at $0.52 per share on June 30, 2026, well below the threshold, and faces potential delisting if the split is not approved or implemented.

• · The company received a Nasdaq deficiency letter on March 19, 2026, for non-compliance with the $1.00 minimum bid price requirement.
• · The initial compliance deadline is September 15, 2026, with the company intending to request an extension.
• · If the stock price closes at $0.10 or less for ten consecutive trading days, Nasdaq will initiate delisting proceedings.
• · The reverse split will not change the number of authorized shares (200,000,000) or the par value of Common Stock.
• · Post-split, the trading symbol will change to 'VBIO'.
• · The Board may abandon the reverse split at any time before filing the amendment with the Delaware Secretary of State.
• · The reverse split has an anti-takeover effect by increasing authorized but unissued shares relative to outstanding shares.
• · The company acknowledged negative investor perception of reverse stock splits and the risk of post-split price declines.

17-07-2026

Glucotrack, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders to be held on August 18, 2026. The filing includes proposals to elect six directors, an advisory vote on executive compensation, ratification of CBIZ CPAs P.C. as auditor, approval of a reverse stock split (aggregate ratio up to 1-for-30), and approval of a warrant inducement to comply with Nasdaq Listing Rule 5635(d). Notably, the company completed a merger with Lokahi Therapeutics on July 14, 2026, and the proxy statement reflects the post-merger board composition, including new CEO Erik Emerson.

• · The company completed a merger with Lokahi Therapeutics on July 14, 2026, with Lokahi surviving as a direct wholly owned subsidiary.
• · Erik Emerson became CEO and director in 2026 following the merger.
• · Proposal 4 seeks approval for a reverse stock split at an aggregate ratio not to exceed 1-for-30.
• · Proposal 5 seeks approval of a warrant inducement to comply with Nasdaq Listing Rule 5635(d).
• · The board currently has six members, all nominated for re-election.
• · Erin Carter joined Masimo Corporation as SVP of Corporate Development and Strategic Finance in November 2025.

17-07-2026

SilverBox Corp IV filed a DEF 14A proxy statement on July 17, 2026, requesting shareholder approval for an extension amendment and a redemption limitation amendment to allow the company more time to complete an initial business combination. The filing details significant risks, including potential CFIUS review and other regulatory hurdles, the possibility of NYSE delisting if listing requirements are not met, and the risk that even if the amendments pass, the company may still be unable to complete a business combination, leaving warrants worthless. These uncertainties present a mixed outlook for shareholders, as the extension offers continued opportunity but also carries substantial downside risks.

• · Filing date is July 17, 2026, referencing the Annual Report for the year ended December 31, 2025.
• · The company's units, Class A ordinary shares, and warrants are listed on the NYSE.
• · For initial listing post-business combination, the share price must generally be at least $4.00 per share.
• · If delisted from NYSE, the company could face penny stock classification, reduced liquidity, and limited analyst coverage.
• · The company notes that if the extension and redemption limitation amendments are approved, public shareholders will have a redemption right both in connection with the extension amendment and again in connection with any shareholder vote on a business combination.